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Introduction
Carbonic anhydrases (CAs) are a family of zinc metalloenzymes
that catalyze the rapid reversible hydration of carbon dioxide to
bicarbonate and protons (Svastova et al., 2003). At least 13 human
CA isoenzymes that exhibit catalytic activity are distributed in
various human organs, tissues and subcellular compartments,
playing an important role in essential cellular processes such as
pHe and pHi regulation, secretion of electrolytes, respiration and
biosynthetic reactions that require CO2 and HCO3– as substrates
(e.g. lipogenesis, gluconeogenesis and ureagenesis) (Thiry et al.,
2006; Zatovicova et al., 2005). CA9, the only transmembrane CA
isoenzyme with an extracellular active site and an NH2-terminal
proteoglycan-like region, is also implicated in cell adhesion as
well as in acid-base balancing and intercellular communication
(Robertson et al., 2004; Svastova et al., 2003). CA9 expression is
most notably induced by hypoxic conditions under tight regulation
by hypoxia-inducible factor 1 alpha (HIF1-) and has been shown
to be distributed at perinecrotic areas in neoplastic tissues
(Giatromanolaki et al., 2001; Wykoff et al., 2000). Such finding
suggests that extracellular acidification by CA9 might be closely
associated tumorigenic transformation, breakdown of the
extracellular matrix, induction of cell growth factors and protease
activation in a hypoxic microenvironment (Thiry et al., 2006). In
our previous study, tumors with high expression of CA9 in primary
tumor tissues were associated with a higher incidence of lymph
node metastasis and poor prognosis (Kim et al., 2006; Lee et al.,
2007). When expression of CA9 was examined in primary cervical
tumor tissues and their surgically-dissected matching lymph nodes
(LN), the primary tumors that showed high CA9 expression also
showed high CA9 expression in the matching metastatic LNs,
which suggests that the CA9-expressing clones in tumors are
metastatic clones (Lee et al., 2007).
Metastasis is one of the hallmarks of malignancy and the most
common cause of death in cancer patients (Yang et al., 2004). The
metastatic process comprises a complex series of steps, which
starts with a loss of cell–cell adhesion, an increase in cell motility
and augmented invasiveness into the surrounding tissues. This
process involves an epithelial-mesenchymal transition (EMT),
which contributes to the dissemination of epithelial cancer cells
(Imai et al., 2003; Yang et al., 2004).
To search for the key regulators of metastasis related to CA9
expression under hypoxic conditions, we established a cell line
that constitutively expresses CA9 using the C33A human cervical
cancer cell line (Shin et al., 2008). We then further investigated
differentially expressed gene profiles in CA9-transfected C33A
cervix cancer cells (C33A/CA9) compared with vector-only-
transfected cells (C33A/Mock) (Shin et al., 2008), using the
Affymetrix Human Genome U133 Plus gene chip assay. Because
our previous studies consistently revealed the high metastatic
potential in tumors where CA9 is overexpressed (Kim et al., 2006;
Lee et al., 2007), we focused on the gene ontology categories
related to metastatic phenotypes. The respective gene functions
included cellular cytoskeletal remodeling, focal adhesion, cell-cell
adhesion and migration. In this study, a series of genes that were
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differentially expressed more than 2-fold, which are related to the
above-mentioned cell functions, were investigated. As genes
involved in Rho-GTP-kinase pathway were also differentially
expressed between the two cell lines, the roles for other selected
genes were investigated in association with Rho/Rho kinase activity.
Results
Differentially expressed gene profiles in a CA9-transfected
C33A cell line
As a result of DNA microarray analysis using Human U133 Plus
2.0 ChIP, a total of 463 genes were shown to be differentially
expressed between the C33A/CA9 and the C33A/Mock cells, of
which 228 were upregulated and 235 were downregulated by more
than twofold. Among those genes, 148 upregulated and 136
downregulated genes had known biological functions. Biological
data mining showed that most of the genes were associated with
cell growth, cell morphology and cell motility. Further exploration
was made for the genes related to cytoskeleton organization and
cell adhesion. Genes regulating cytoskeletal organization and cell
adhesion (ARHGDIA, restin, vimentin, paxillin, talin, etc.) were
upregulated in C33A/CA9 cells compared with the C33A/Mock
cells, whereas the genes involved in Rho-GTPase activation and
the retention of the extracellular matrix (THBS1, TIMP2, FGD6,
CDC42EP3, etc.) were downregulated in the C33A/CA9 as
compared with the C33A/Mock cells (Table 1). Expression of
these genes was confirmed by reverse-transcriptase PCR (RT-PCR)
and quantitative RT-PCR. The correlation between gene expression
profiles and quantitative RT-PCR was ascertained in seven selected
genes including CA9 (Fig. 1). The same results were confirmed
using polyclonal C33A/Mock and polyclonal C33A/CA9 cells in
order to demonstrate that the changes observed in C33A/CA9 cells
were not due to different clonality (data not shown).
Effect of CA9 on formation of actin stress fiber and focal
adhesion
On the basis of microarray analysis, it was decided to investigate
the role for CA9 in actin cytoskeleton reorganization and cellular
adhesion. C33A/CA9 and C33A/Mock cells were plated onto
Matrigel basement membrane matrix extracted from the Engelbreth-
Holm-Swarm (EHS) mouse sarcoma, a tumor rich in extracellular
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Table 1. The list of differentially expressed genes in C33A/CA9 cells compared with in C33A/Mock cells
Gene ontology Gene ID number Gene name
Fold change
(FC)
NM_001216 Carbonic anhydrase IX (CA9) 5.14Carbon compound metabolism
Cell growth; regulation of cell size NM_002045 Growth associated protein 43 7.61
NM_001423 Epithelial membrane protein 1 (EMP1) 6.89
AI809967 SHC (Src homology 2 domain containing) transforming protein 1 2.43
NM_003377 Vascular endothelial growth factor B 2.01
NM_006747 Signal-induced proliferation-associated gene 1 2.07
AF051344 Latent transforming growth factor beta binding protein 2.08
Cell adhesion AI571798 Rho GDP dissociation inhibitor (GDI) alpha (ARHGDIA) 4.07
AF498927 Rho GDP dissociation inhibitor (GDI) beta (ARHGDIB) 2.08
NM_004343 Calreticulin 3.95
NM_001464 A disintegrin and metalloproteinase domain 2 (fertilin beta) (ADAM2) 5.14
Regulation of signal transduction NM_012242 Dickkopf homolog 1(Xenopus laevis) (DKK1) 13.63
NM_016431 Mitogen-activated protein kinase 8 interacting protein 2.02
AB016929 Regulator of G-protein signaling 11 2.01
AA775681 Chromosome 1 ORF 139 2.04
BE045549 Mindbomb homolog 2 (Drosophila) 2.32
U79264 Zic family member 1 (odd-paired homolog, Drosophila) 2.10
D86862 Paxillin 2.24
AF188179 Guanine nucleotide binding protein (G protein), gamma 8 2.73
BF673049 Restin (Reed-Steinberg cell-expressed intermediate filament) 2.06Intermediate filament; structural
constituent of cytoskeleton NM_021076 Neurofilament, heavy polypeptide 200 kDa 4.20
AI922599 Vimentin 2.53
S62137 Dopamine receptor D2 2.04
NM_006950 Synapsin 1 2.16
NM_006289 Talin 1 2.57
NM_004877 Glia maturation factor, gamma 2.30
NM_022359 Phosphodiesterase 4D interacting protein 3.01
NM_003282 Troponin 1, skeletal, fast 2.16
AA912711 Erythrocyte membrane protein band 4.1-like 1 3.00
AI358867 Apolipoprotein E 2.04
AF143684 Myosin IXB 2.06
NM_006790 Titin immunoglobulin domain protein (Myotilin) 6.30
NM_005775 Vinexin beta (SH3-containing adaptor molecule-1) 2.69
Adhesive glycoprotein BF055462 Thrombospondin 1 (THBS 1) 0.25
Blood coagulation BF983379 CD59 antigen p18-20 (CD59) 0.46
Protease inhibitor BE968786 Tissue inhibitor of metalloproteinase 2 (TIMP2) 0.46
Regulation of body fluid J03225 Tissue factor pathway inhibitor (lipoprotein-associated coagulation
inhibitor)
0.39
Enzyme inhibitor NM_001262 Cyclin-dependent kinase inhibitor 2C 0.43
Actin binding; protein binding AF010314
NM_005010
Ectodermal-neural cortex (with BTB-like domain) (ENC1) 0.17
AL136842
Neuronal cell adhesion molecule (NRCAM) 0.43
CDC42 effector protein (Rho GTPase binding) 3 (CDC42 EP3) 0.45Guanyl-nucleotide exchange factor
activity NM_018351 FYVE, Rho GEF and PH domain containing 6 (FGD6) 0.40











matrix proteins. When the cells were stained with phalloidin
conjugated with Alexa 488 and anti-vinculin antibody labeled with
Alexa 594 to visualize actin stress fibers and focal adhesion
complexes, it was observed that the C33A/CA9 cells had relatively
thicker and shorter actin bundles restricted to the cellular periphery
and actin-rich membrane protrusions at leading edges. The number
of focal adhesion complexes visualized by vinculin were higher
and more prominent in C33A/Mock cells, whereas vinculin
expression was more concentrated at the end of the membrane
protrusion complexes and appeared to be diminished in number
and size in most of the C33A/CA9 cells (Fig. 2A,B). This pattern
was very similar to the morphological changes of HeLa cells in
which CA9-expression was greatly stimulated by hypoxic
conditions (Fig. 2B) (Shin et al., 2008). The expression and tyrosine
phosphorylation of paxillin, a major regulator in organization and
function of focal adhesions, were assessed by western blot analysis
(Fig. 2C). Interestingly, both the expression level and
phosphorylation level at Tyr118 of paxillin were increased in
C33A/CA9 cells, which supported the increase in paxillin
expression in microarray analysis (Table 1). Supplementary material
Fig. S1 shows the basal level of CA9 expression and its change
under hypoxic conditions in C33A cell lines. Tissues from the
invasive cervix carcinomas with negative and strong expression of
CA9, respectively, were selected and examined for CA9 expression
by western blot and immunohistochemical staining.
CA9 is associated with increased cell migration and
invasion
Unlike C33A/Mock cells, which mostly showed a general flattened
shape with a number of actin stress fibers transversing the entire
cell body, C33A/CA9 cells showed cytoskeletal changes leading to
a stellate morphology. C33A/Mock cells maintained steady focal
adhesions; however, C33A/CA9 cells showed miniature focal
adhesions on Matrigel-coated plates (Fig. 2A,B). In addition to
this, C33A/CA9 cells grown in the 3D Matrigel culture showed
severely compromised cell-to-cell adhesion and increased cell
motility, which was indicated by the appearance of loose clumps
with multiple budding of the cells into the surrounding Matrigel
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Fig. 1. The list of differentially expressed genes in C33A/CA9 and
C33A/Mock cells. Differentially expressed genes were selected on the basis of
fold-change in CA9-overexpressed (C33A/CA9) cells versus vector-
transfected control (C33A/Mock) cells. Gene expressions were confirmed by
RT-PCR and quantitative RT-PCR. The relative quantity for each molecule was
normalized with GAPDH, which was used as an internal control. Each bar
represents the mean (plus standard error) of four independent experiments.
*P<0.05.
Fig. 2. Reorganization of actin cytoskeleton and alteration of focal
adhesion induced by CA9 overexpression. (A)C33A/CA9 and C33A/Mock
cells were incubated on glass slides pre-coated with BD Matrigel Matrix with
the cultured medium for 24 hours. Actin filaments (green) of cytoskeleton,
vinculin (red) of focal adhesion complex and nuclear DNA (blue) were stained
with phalloidin conjugated with Alexa 488, anti-vinculin antibody labeled with
Alexa 594 and DAPI, respectively. (B)HeLa cells were cultured under
normoxic (20% O2) and hypoxic (0.1% O2) conditions and were stained in the
same manner as in A. (C)Cells grown as described above were harvested and
CA9 expression was confirmed using M75 monoclonal antibody. Expression
and phosphorylation of paxillin was examined by immunoblotting, using the












stroma. This was in contrast to the C33A/Mock cell culture where
densely aggregated clumps of cells were observed (Fig. 3A).
Similar results were obtained in a Transwell chamber assay
performed to quantify the migratory and invasive cells (Fig. 3B,C).
Each bar represents the mean (plus standard error) of six
independent experiments. Migrating and invading cells were
significantly promoted in C33A/CA9 cells compared with
C33A/Mock cells (unpaired t-test, P0.0305 and 0.0375 for the
migration and invasion assay, respectively; Fig. 3B,C).
Rho-GTPase signaling is involved in cellular morphologic
and migratory changes
To further clarify the molecular mechanism underlying these
phenotypes associated with CA9, we focused on Rho-GTPases,
which are known as key regulators of actin cytoskeleton formation
and cellular adhesion through their interaction with downstream
effector proteins (Ren et al., 1999). Rho-GTPase receives upstream
signals through regulators such as GDP–GTP exchange protein
(GEP), GDP dissociation inhibitor (GDI) and GTPase activating
protein (GAP), which modulates shuttling between the inactive
GDP-bound and the active GTP-bound forms, thus transmitting
signals to downstream effectors such as Rho kinase (ROCK) (Kim
et al., 2007; Ren et al., 1999). By examining microarray data, we
observed that GDI, which interacts with the GDP-bound form and
prevents it from being converted to the GTP-bound form, was
increased, whereas CDC42EP3 [also known as small GTPase
effector protein 3 (CEP3)] was decreased in C33A/CA9 cells
(Table 1; Fig. 1). Western blot analysis also showed a reduction of
the GTP-bound active form in C33A/CA9 cells (Fig. 4A),
supporting the gene expression result. Furthermore, we investigated
changes in cell morphology, adhesions and migration after
inhibition of Rho signaling by blocking ROCK with the selective
inhibitor Y27632 (Biosource). In this experiment, cells received a
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Fig. 4. Rho-GTPase activity and changes in cytoskeletal structure and
focal adhesion with CA9 overexpression. (A)The amount of GTP-bound
Rho-GTPase was compared between two cells by GST-RBD pull-down assay.
Band intensity of activated RhoA/B/C-GTPases was quantified by image
software, Multi Gauge, V3.0 (FUJIFILM). (B)Changes in actin cytoskeleton
and focal adhesions subsequent to blocking the Rho downstream with ROCK
inhibitor (Y27632) were observed by immunofluorescence analysis.
C33A/Mock and C33A/CA9 cells were plated as in Fig. 2A and treated with a
final 10M Y27632 after 3 hours. Actin filaments, vinculins and nuclear DNA
were stained as green, red and blue signal, respectively. (C)Total lysates from
two cell line cultures treated with or without 10M Y27632 as described in B
were used for immunoblotting for expression and phosphorylation of paxillin.
-actin was used as a loading control.
Fig. 3. Increased invasive and metastatic ability with CA9 overexpression.
(A)C33A/CA9 and C33A/Mock cells were suspended as single cells and were
cultured in Matrigel for two weeks. Images of the spheroid colonies were
acquired using a light microscope (100 magnification). (B,C)Migratory and
invasive ability of two cell lines were examined using Transwell chambers
with or without Matrigel coating. The cells migrating through the filters were
enumerated and the relative ratio of migrating C33A/CA9 cells to migrating
C33A/Mock cells was determined. Each illustration shows the typical image
and each bar represents the mean (plus standard error) of six independent











treatment of 10 M ROCK inhibitor Y27632 on a Matrigel matrix
for 20 hours. The effect of Y27632 was more profoundly observed
in C33A/Mock cells, changing the shape of the cells into stellate
morphology with formation of thicker and shorter actin stress
fibers compared with the pre-treatment cell (C33A/Mock-CNT)
morphology. Focal adhesions of the cells to the stroma were shown
only in the leading edge of the cell–stroma contact and were
disassembled overall (Fig. 4B). The expression and tyrosine
phosphorylation of paxillin were remarkably increased in
C33A/Mock cells after Y27632 treatment (Fig. 4C). In addition,
the tight cell-to-cell contact that was observed in 3D Matrigel
culture of C33A/Mock cells was remarkably diminished and many
budding daughter clumps were observed with Y27632 treatment
(Fig. 5A). Migrating and invading cells were also significantly
increased after Y27632 treatment compared with C33A/Mock-
CNT cells (Fig. 5B,C). Each bar represents the mean (plus standard
error) of six independent experiments. However, cell adhesion and
motility between the C33A/CA9-CNT cells and the C33A/CA9
cells treated with Y27632 was not significantly different, suggesting
that the C33A/CA9 cells were not significantly influenced by
Y27632 treatment (Fig. 5A–C) and that there was constitutively
low Rho kinase activity in this cell line.
CA9-induced Rho inactivation leads to epithelial–
mesenchymal transition
According to the previous reports, Rho-GTPases are implicated in
EMT owing to their involvement in dissociation of cell adhesions
and cytoskeletal remodeling (Patel et al., 2005; Tumbarello et al.,
2005). Therefore, we examined the expression of epithelial markers
such as E-cadherin and -catenin and mesenchymal markers such
as vimentin and N-cadherin by western blot analysis. The
expression of E-cadherin and -catenin was stronger in C33A/Mock
cells than in C33A/CA9 cells and its expression was reduced by
treatment with Y27632 in C33A/Mock cells. By contrast, the
expression of mesenchymal proteins, particularly vimentin was
strongly increased in C33A/CA9 cells compared with C33A/Mock
cells (Fig. 6C). After Y27632 treatment, the expression of
mesenchymal markers was reversed in C33A/Mock cells; however,
C33A/CA9 cells did not show changes after the same treatment,
suggesting that the EMT process is strongly activated by
constitutively high expression of CA9 and low Rho-GTPase activity
in this cell line. The quantitative measurement of proteins related
to EMT was also observed by immunofluorescent staining of the
same proteins. E-cadherin was generally distributed in the cell
membrane of C33A/Mock cells, whereas it was diffusely distributed
in low levels within the cytoplasm and not in the cell membrane
of C33A/CA9 cells. The Y27632-treated C33A/Mock cells showed
weakening and changes of distribution in E-cadherin with a
dramatic change in cell shape. In C33A/CA9 cells, vimentin
filaments appeared to be extended along the cell periphery to the
nucleus and were distributed more on the leading region. After
Y27632 treatment, a similar appearance to C33A/CA9 cells was
also observed in C33A/Mock cells (Fig. 6A,B). The observation
that Y27632-induced Rho signaling inhibition in C33A/Mock cells
leads to a phenotypic change similar to that of the C33A/CA9 cells
in terms of increased migratory activity and increased mesenchymal
protein expression suggests that the increased migratory and
invasive phenotype of C33A/CA9 cells are attributed to the aberrant
Rho signaling by Rho-GTPase inactivation. The phenotypic
characteristics observed by the treatment with Y27632 were also
reproduced by siRNA-mediated Rho A silencing (Fig. 7A,B),
which confirms the role for decreased Rho activity in phenotypic
changes of C33A/CA9 cells. To demonstrate whether the above
results were induced by CA9 overexpression, we performed a
siRNA-mediated CA9 silencing experiment (Fig. 8). As a result,
we confirmed that activity of Rho, but not the other small GTPases
such as ras-related C3 botulinum toxin substrate 1 (RAC1) and cell
division control protein 42 (CDC42), is strongly influenced by
CA9 expression. Changes in paxillin and EMT markers shown in
C33A/CA9 cells were restored to a similar level to that of
C33A/Mock cells after silencing of CA9 expression (Fig. 8A,D).
The migratory and invasive ability of C33A/CA9 cells was nearly
as low as that of C33A/Mock cells with inhibition of CA9 by
siRNA (Fig. 8B,C).
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Fig. 5. Migratory and invasive potential improved with Rho-GTPase
inactivation in C33A/CA9 cells. (A)C33A/Mock and C33A/CA9 cells were
cultured in Matrigel for 8 days, as in Fig. 3A and were treated with final
10 M Y27632 at this time to start cells clumping. Y27632 inhibitor was
treated two more times and the cells were observed using a light microscope
(100 magnification). (B,C)Migrating and invading ability of the cells were
examined as in Fig. 3B and 3C. Cells were seeded onto respective Transwell
chambers and were treated with 10 M Y27632 3 hours after seeding. Each
figure illustrates the typical image obtained and each bar represents the mean











CA9 directly interacts with DKK1
To understand the working mechanism of CA9, we investigated
CA9 binding proteins using a yeast two-hybrid interaction assay
system. One prominent protein identified was dickkopf homolog 1
(DKK1), which was also detected in microarray analysis with a
13.6-fold increase in C33A/CA9 cells compared with C33A/Mock
cells. Positive interaction was observed by using both cell growth
and -galactosidase activity (Fig. 9A). As shown in Fig. 9A,
positive -galactosidase activity was observed in the CA9–DKK1
system, whereas very little -galactosidase activity was observed
in the CA9–empty-vector system. To further confirm the direct
interaction between CA9 and DKK1 that we observed in the yeast
two-hybrid system, we performed co-immunoprecipitation (Co-
IP). pcDNA3.1–DKK1 was co-immunoprecipitated with pcDNA
and Flag-CA9, whereas no interaction was observed between
pcDNA3.1 (vector only) and pcDNA3.1 with Flag–CA9 (Fig. 9B).
An immunoblotting assay using anti-CA9 antibody confirmed that
an equal amount of CA9 was precipitated in both samples (Fig.
9B). The interaction of the two proteins was also revealed by Co-
IP of endogenous CA9 and DKK1 (Fig. 9C). These results clearly
indicated that CA9 directly interacts with DKK1 at a physiological
level.
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Fig. 6. The role of Rho-GTPase signaling
in the EMT process. (A)The expression and
localization of E-cadherin and vimentin were
examined by immunofluorescence analysis.
Prepared under the same conditions as in Fig.
4B, the cells were stained for E-cadherin
(red) and vimentin (green) with Alexa-594-
and Alexa-488-labeled secondary antibodies,
respectively. (B)Thirty micrograms of the
membranous and cytoplasmic fraction of
proteins obtained from the cells were loaded
and the expression of E-cadherin was
analyzed by western blotting. PMCA4
(plasma membrane calcium ATPase 4) and -
tubulin were used as controls for
membranous and cytoplasmic proteins,
respectively. (C)Expression of epithelial
markers (E-cadherin and -catenin) and
mesenchymal markers (vimentin and N-
cadherin) were examined by western blot in
both C33A/Mock and C33A/CA9 cells, with
or without Y27632 treatment. -actin was
used as a loading control. Band intensity
from western blot images was quantified by
Multi Gauge V3.0 (FUJIFILM). Each bar












Recent studies have reported the important role for the tumor
microenvironment in association with invasive and aggressive
phenotypes (Mueller and Fusenig, 2004; Quaranta and Giannelli,
2003). Destabilization of intercellular contacts, increased cell
motility, altered tissue morphogenesis and remodeling, acidification
of extracellular pH and increased activity of tissue proteinase
involved in the breakdown of the extracellular matrix are known
to be required for the process of metastasis to occur. CA9 has not
only an enzyme activity to induce the acidification of extracellular
pH, but also physical function to perturb tight intercellular contacts
linked to the cytoskeleton through competition with E-cadherin in
binding with -catenin (Mueller and Fusenig, 2004; Svastova et
al., 2003). In this study, we showed that the transcriptional level of
many genes, and hence aberrant signal transduction related to cell
adhesion and cytoskeletal organization, can be induced by
overexpression of CA9. Immunofluorescent staining of actin
filaments and focal adhesion complex proteins revealed dramatic
changes in CA9-transfected cells that were similar to the pattern of
HeLa cells exposed to a concentration of 0.1% oxygen, thus
indicating that the observed changes in CA9-overexpressing C33A
cells are one of the underlying mechanisms of increased metastatic
potential of the cancer cells under a hypoxic microenvironment.
As genes related to Rho/Rho kinase signal transduction pathway
were changed at the same time in CA9-expressing cells and because
Rho-GTPases and Rho kinase activity are known to regulate a
variety of cellular functions such as cytoskeletal reorganization,
cell-cell adhesion, cell cycle progression and motility, we
investigated whether this pathway was the underlying mechanism
of CA9-related phenotypic changes. Rho-GTPases, including the
classical Rho, RAC and CDC42, regulate the above-mentioned
cellular functions through upstream pathways, cycling between an
inactive GDP-bound form and an active GTP-bound form under
regulation by GEFs, GAPs and GDIs (Guo et al., 2006; Ridley,
2001; Togawa et al., 1999), and downstream pathways carried by
Rho kinase and p21-activated kinases. Upon active GTP-bound
state targeting to the membrane fraction, GTPases transmit signals
from cell-surface receptors to intercellular target molecules via
several different pathways. Specifically, Rho stimulates the
formation of actin stress fiber and focal adhesion, whereas CDC42
activation triggers the extension of filopodia and RAC controls
growth-factor-stimulated membrane ruffling and formation of
lamellipodia. Recently, Rho-GTPase-directed mechanisms were
suggested to play a key role in EMT (Holtje et al., 2005; Patel et
al., 2005) through the extensive crosstalk between the three
GTPases (Holtje et al., 2005; Nimnual et al., 2003; Yamaguchi et
al., 2001), altering the activation status of the respective GTPases.
In addition to this, previous studies showed that inactivation of
RhoA either by direct inhibition with exoenzyme C3 or by blocking
downstream targets such as ROCK with Y27632 contributed to
enhanced migration and EMT while maintaining expression of
active RAC1 and CDC42 (Holtje et al., 2005; Patel et al., 2005).
Our experimental results are also in line with these observation
because migratory and invasive ability were enhanced with the
induction of mesenchymal markers in C33A/Mock cells when
Rho-GTPase downstream signaling was blocked by Y27632 and
specific siRNAs against RhoA. In addition, recent studies showed
that Tyr31/118 phosphorylation of paxillin competes with
p190RhoGAP for binding to p120RasGAP and provided evidence
that p190RhoGAP freed from p120RasGAP efficiently suppressed
RhoA activity during cell adhesion to the ECM (Jagadeeswaran et
al., 2008; Tsubouchi et al., 2002; Zaidel-Bar et al., 2007). Paxillin,
a focal adhesion scaffolding protein, not only plays a crucial role
in dynamic changes of focal adhesion and binding to other focal
adhesion proteins such as FAK, vinculin, talin and tensin, but also
affects the regulation of cell spreading, motility and muscle
differentiation. The latter functions are known to be a result of the
direct interaction with multiple structural and signaling proteins
such as tubulin, p120RasGAP, PKL, PTP-PEST, SRC, CRK and
CSK (Iwasaki et al., 2002; Jagadeeswaran et al., 2008; Tumbarello
et al., 2005; Zaidel-Bar et al., 2007). A link between tyrosine
phosphorylation of paxillin and Rho activity was observed in our
study. Our results showed that the suppression of Rho signaling
induced tyrosine phosphorylation of paxillin and subsequently
activated paxillin-transmitted signals, which promote dynamic
adhesion turnover and cell migration.
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Fig. 7. Rho signaling is crucial to form the
migratory phenotypes. The role of Rho signaling was
validated using two types of siRNAs against RhoA at a
concentration of 25 nM. A double-stranded non-
specific siRNA was used as a negative control (CNT).
(A)Block efficiency of si-Rho and quantitative
changes of EMT markers were analyzed by western
blot. -actin was used as a loading control. (B)An
invasion assay using Transwell chambers with Matrigel
coating was repeated six times. The cells migrating
through the filters were enumerated and the relative
ratio of invasive cells was normalized by the number of
migrating C33A/Mock-CNT cells. Illustrations show












The previous study of Pastorekova et al. (Svastova et al., 2003)
showed a relationship between CA9 and E-cadherin in cell
adhesion, whereas we showed the effect of CA9 on Rho/ROCK
signaling transduction and EMT in the current study. Tracing the
upstream signal in these relationships, we found that CA9 directly
binds to the secreted protein DKK1, which is known as one of the
transcriptional target genes along with vimentin, fibroblast growth
factor 20 (FGF20) in the Wnt/-catenin/TCF signaling pathway
(Chamorro et al., 2005; Kuang et al., 2009; Schlessinger et al.,
2009; Orsulic et al., 1999). Interaction of CA9 and DKK1 might
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Fig. 8. The effect of CA9 on migration and invasion is validated by siRNAs against CA9. (A)Block efficiency of si-CA9 was validated by western blot. A
double-stranded non-specific siRNA was used as a negative control (CNT). C33A/CA9 cells were transfected with 150 nM siRNA against CA9 for 24 hours and
then were transferred onto Matrigel-coated dishes. After incubation for 24 hours, total cell lysates were analyzed for small GTPases such as Rho, RAC, CDC42 and
paxillin using a pull-down assay and western blot analysis. Band intensity from western blot images was quantified by Multi Gauge V3.0. (B,C)At 24 hours post-
transfection, the cells were prepared for migration and invasion assays as in Fig. 5B and C. (D)Cells were prepared as in Fig. 8A and were analyzed for EMT
markers by western blot analysis. After silencing of CA9 expression, epithelial markers increased in expression, whereas mesenchymal markers decreased in











induce a conformational change of CA9 and prevent GDP-Rho
from moving to the coupled receptor on the cell membrane, which
in turn blocks interaction with Rho-specific effectors such as GEFs
and GAPs. Although future studies will be required to fully
elucidate the mechanism underlying CA9–DKK1 interaction and
CA9–DKK1-mediated RhoA/ROCK signaling pathway, our present
findings provide important new insights into tumor-associated cell
migration and invasion. Overall, we suggest that overexpression of
CA9 contributes to increasing metastatic potential through
interference with the Rho/ROCK signaling pathway, which might
be associated with CA9–DKK1 interaction and transcriptional
regulation of the -catenin signaling pathway.
Materials and Methods
Cell culture and stable transfection of C33A cells
The human cervical cancer cell line C33A (ATCC number HTB-31) was stably
transfected with either full-length human CA9 cDNA cloned into the pcDNA3
vector or empty vector control (Shin et al., 2008). Transfected polyclonal cell
populations were selected for growth in the presence of 250 g/ml G418 (GIBCO-
BRL, Gaithersburg, MD) for 3 weeks. Selected monoclonal CA9-transfected cells
(C33A/CA9) and vector-only-transfected cells (C33A/Mock) were tested for
expression of CA9 as previously described by real-time PCR and western blot
analysis (Shin et al., 2008). M75, the monoclonal antibody for CA9, was a kind gift
from Silvia Pastorekova (Slovak Academy of Sciences, Slovakia). Cells were
maintained at 5% CO2 in RPMI (for C33A cells) or MEM (for HeLa cells) medium
with 10% fetal bovine serum supplemented with 1% streptomycin and penicillin.
RNA isolation and microarray analysis
Total RNA was extracted from the cells using a TRIzol (Invitrogen, Carlsbad, CA)
method, followed by cleanup with the RNeasy Mini Kit isolation method (Qiagen
GmbH, Hilden, Germany). Microarray was performed using 5 g total RNA and
Affymetrix Human Genome U133 Plus 2.0 arrays (Affymetrix, Santa Clara, CA)
containing ~54,675 total probes and 63 control probes. We performed synthesis of
biotin-labeled cRNA from total RNA samples and hybridization on Affymetix arrays,
according to the Affymetrix standard protocols. After staining, intensities were
determined with a GeneChip Scanner 3000 (Affymetrix). Scanned data were pre-
processed with an RMA (robust multi-array average) procedure using only perfect
match (PM) probe intensities for background adjustment (Irizarry et al., 2003). RMA
was preceded by quantile normalization (Bolstad et al., 2003) and median
polish summarization of PM intensities (Irizarry et al., 2003). The differentially
expressed genes with over 2-fold change were selected to analyze the biological
inter-relationship. Genplex software, version 3.0 (ISTECH Inc., Goyang-si,
Republic of Korea), was used for the biological data mining. Specification of the
many gene annotations was also supplemented by further online database searches.
Microarray data have been deposited in the Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo/) and are accessible through Gene Expression
Omnibus series number GSE20569.
Reverse transcriptase-PCR (RT-PCR) and quantitative RT-PCR
For validation of microarray data, a total of seven genes associated with cell growth,
morphology and motility, including CA9, were selected for RT-PCR and quantitative
RT-PCR. The RT-PCR and quantitative RT-PCR were carried out as previously
described (Kim et al., 2006). The primer sequences used for RT-PCR were as
follows: CA9 (Forward) 5-TAAGCAGCTCCACACCCTCT-3, (Reverse) 5-
TCTCATCTGCACAAGGAACG-3; ARHGDIA (Forward) 5-CTTGATG -
GTGAGATTCCACT-3, (Reverse) 5-TGAAGTACATCAGCCATACG-3; DKK1
(Forward) 5-CACTGATGAGTACTGCGCTA-3, (Reverse) 5-CAGAA -
CCTTCTTGTCCTTTG-3; vimentin (Forward) 5-GAGAGGAA GCCG AAA -
ACACC-3, (Reverse) 5-GCTTGGAAACATCCACATCG-3; CEF3 (Forward)
5-TCAGGAGAAAAGCAGTCTGT-3, (Reverse) 5-GAGAGGGACTC -
CTCTGACTT-3; THBS1 (Forward) 5-CTGGACAACTGTCCCTATGT-3,
(Reverse) 5-AAATCGGTCTCACTGATGTC-3; FGD6 (Forward) 5-CCCA -
GACATCAGCATTCCAG-3, (Reverse) 5-AGCTACTGCATCCCGGAAAT-3;
GAPDH (Forward) 5-TCATTGACCTCAACTACATGGT-3. TaqMan pre-designed
assays of each gene were provided by Applied Biosystems (Foster City, CA) for
quantitative RT-PCR. Assay IDs are as follows: ARHGDIA, Hs00976924 g1; DKK1,
Hs00183740 m1; vimentin, Hs00958116 m1; THBS1, Hs00962908 m1; FGD6,
Hs00217947 m1; CDC42EP3, Hs00377831 m1.
Immunofluorescence analysis
Cells were attached onto glass slides coated with 500 g/ml BD Matrigel Basement
Membrane Matrix (BD Biosciences, San Jose, CA) for 24 hours, kept under the
medium and cultured with respective cell lines for 4 days and then were fixed in
3.7% formaldehyde for 20 minutes at room temperature. The cells were permeabilized
with 0.1% Triton X-100 for 5 minutes at room temperature and were treated with
1% BSA in TBST (TBS containing 0.2% Tween 20) to block nonspecific reaction.
Sequential incubation of primary antibody (Upstate Biotechnology, Waltham, MA)
and Alexa fluorescence-conjugated secondary antibody (Molecular Probes, Eugene,
OR) was performed with DNA stained with DAPI (Molecular Probes). For hypoxic
experiments for HeLa cells, the cells were incubated under hypoxic (0.1% O2) and
normoxic (20% O2) conditions for 18 hours before immunofluorescent staining. The
stained cells were mounted with DAKO mounting medium (DAKO Corporation,
Carpinteria, CA) and were examined using a confocal laser scanning microscope
(Zeiss LSM 510 META, Car Zeiss Microimaging, Inc., Thornwood, NY) at 400
magnification. The primary antibodies used were vinculin (Sigma-Aldrich, St Louis,
MO), E-cadherin (BD Transduction Laboratories, San Jose, CA), vimentin (BD
Pharmingen, San Diego, CA), and phalloidin (Molecular Probes).
Subcellular fractionation
To prepare the differential extraction of proteins from monolayer-cultured cells
according to their subcellular localization, we used the ProteoExtract Subcellular
Proteome Extraction Kit (Calbiochem, San Diego, CA). Cells cultured on 500 g/ml
Matrigel-coated 100 mm plates were lysed and subcellular components were separated
as recommended by the manufacturer. The cytosol fraction and membrane fraction
proteins were analyzed by western blotting. PMCA4 (plasma membrane calcium
ATPase 4) and -tubulin were used as internal controls for plasma membrane and
cytoplasm proteins, respectively.
Western blot analysis and antibodies
Cells (1106) were cultured on 500 g/ml Matrigel-coated 100 mm plates under the
same culture conditions used for immunofluorescent staining. The cells were washed
twice with cold PBS prior to solubilization in cold lysis buffer containing 50 mM
Tris-HCl (pH 8.0), 0.25 M sodium chloride, 1% NP-40, 1% Triton X-100, 2 mM
CaCl2, 1 mM PMSF and protease inhibitor cocktail (Sigma) for 40 minutes at 4°C.
Lysates were denatured and reduced with 5 SDS sample buffer. Protein samples
(~10-30 g each) were separated by 8% (N-cadherin, E-cadherin and -catenin) or
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Fig. 9. Interaction analysis between human CA9 and
DKK1. (A)Interaction of CA9 with the indicated
proteins using the yeast two-hybrid assay system. Positive
interactions are indicated by the formation of blue
colonies on medium containing X-gal. Binding activity of
CA9 and DKK1 activity was measured by adding ONPG.
Data were expressed as the mean ± s.e.m.
(B)Coimmunoprecipitation of pcDNA3.1– Flag-CA9 and
pcDNA3.1–DKK1. Proteins immunoprecipitated with
anti-Flag antibody were analyzed by western blot analysis
with anti-DKK1 antibody. Data shown are representative
of three independent experiments.
(C)Coimmunoprecipitation between endogenous CA9












12% (CA9, vimentin, paxillin, RhoA/B/C, RAC1, CDC42 and -actin) SDS-PAGE
and transferred to a Hybond–ECL nitrocellulose membrane (GE Healthcare, Little
Chalfont, Buckinghamshire, UK). Membranes were blocked with 3% bovine serum
albumin in TBST and incubated with primary antibodies in blocking solution at 4°C
overnight. After washing with TBST, horseradish-peroxidase-conjugated secondary
antibodies (Cell Signaling Technology, Beverly, MA) were applied and the blots
were developed by the Enhanced Chemiluminescence Detection System (GE
Healthcare Life Sciences). The antibodies used were CA9, a kind donation from
Silvia Pastorekova (Institute of Virology, Slovak Academy of Sciences, Slovak
Republic), -actin (Abcam, Cambridge, UK), vimentin (BD Pharmingen), N-cadherin,
E-cadherin, -catenin (BD Transduction), paxillin (Upstate Biotechnology, Lake
Placid, NY), pPaxillinY118 (Invitrogen), -tubulin (Abcam) and PMCA4 (Santa Cruz
Biotechnology, Santa Cruz, CA).
Three-dimensional multicellular spheroid culture using Matrigel Basement
Membrane Matrix
Matrigel Basement Membrane Matrix (BD Biosciences) was thawed and mixed
homogeneously as recommended by the supplier. Single cells (5103) were suspended
in 600 l Matrigel using cooled pipettes and were allowed to gel on a 24-well plate
for 30 minutes at 37°C. The cells embedded in thick gel were incubated for 4 days in
culture medium containing an equal volume of fresh growth medium and the medium
used to culture the cells in order to magnify the expected effects of CA9 enzymatic
activity. After two weeks, the Matrigel was fixed and stained with Diff-Quik (Kokusai-
Shiyaku, Kobe, Japan) solution. Images of the cells grown in 3D matrix were acquired
using a light microscope (100 magnification; Olympus, Center Valley, PA) with a
digital camera system (Prog-Res C14; Jenoptik, Jena, Germany).
Migration assay
Cell migration assays were performed using 6.5 mm Transwell chambers (Corning
Costar Corp., Cambridge, MA) containing polycarbonate membrane (8 m pore
size). Media cultured with C33A/Mock and C33A/CA9 cells for 4 days was added
to their respective lower chambers and was used to dilute the cells to a concentration
of 5105 cells per 0.5 ml. The cell suspension was added to each upper chamber
and incubated at 37°C for 16 hours. Cells that migrated to the bottom of the plate
through the membrane were fixed and stained with Diff-Quik solution (Kokusai-
Shiyaku) and enumerated using a light microscope (40 or 100 magnification;
Olympus). Each experiment was performed in triplicate wells and repeated two
times. Each bar represents the mean (plus standard error) of six independent
experiments.
Invasion assay
A Matrigel Invasion Chamber (BD Biosciences) was hydrated with 500 l serum-
free medium added to both lower and upper chambers for at least 2 hours at 37°C
in a CO2 incubator. After rehydration of the Matrigel, the lower chamber was
replaced with media cultured for 4 days and the upper chamber was filled with cell
suspension diluted at concentration of 4104 cells per 0.5 ml. The invasion chamber
plate was incubated for 24 hours. Unmigrated cells on the upper side of the Matrigel-
coated insert were removed with cotton swabs and the cells invading through the
Matrigel were fixed and stained with Diff-Quik solution (Suzuki et al., 2005). The
number of cells that invaded the Matrigel layer was quantified following the same
protocol used for the migration assays.
Rho-GTPase activity assay
An activity assay for RhoA/B/C, small GTPases, was conducted with the Rho
Activation Assay Kit (Upstate) according to the manufacturer’s instructions. In brief,
the GST-rhotekin-RBD (Rho binding domain) fusion protein of the Rho Activation
Assay Kit was used to specifically precipitate GTP-Rho, the active form of Rho-
GTPase. The GST-RBD was incubated with total cell lysate at 4°C for 1 hour. The
GTP-Rho pulled down from the lysate was detected by western blot analysis using
anti-RhoA/B/C antibody. Like the preceding pull-down assay, the activity of RAS-
related C3 botulinum toxin substrate 1 (RAC1) and cell division control protein 42
(CDC42) was examined using the GST-PAK1 PBD (p21 binding domain of human
PAK1) reagent, anti-RAC1 and anti-CDC42 antibody (Upstate).
Silencing of gene expression by short interference RNA
Target siRNAs for silencing of human CA9 and RhoA were obtained from Qiagen.
The sequences of the si-CA9 sense strand were 5-GGCUGCUGGUGACAUC -
CUATT-3 and 5-ACCUGAAGUUAAGCCUAAATT-3. The siRNAs against RhoA
are HP Validated siRNA products (SIO2654211 and SIO2654267). A double-stranded
non-specific siRNA (Qiagen) was used as a negative control. The siRNA transfection
was conducted with Lipofectamine 2000 reagent (Invitrogen) according to the
manufacturer’s instructions. Cells plated for 24 hours were transfected with 150 nM
of si-CA9 (two kinds of si-CA9 RNA were mixed at 75 nM each) or with 50 nM of
si-RhoA (two kinds of si-RhoA RNA were mixed at 25 nM each). At 24 hours after
transfection, the cells were prepared for the migration and invasion assays, the Rho-
GTPase activity assay and western blot analysis.
Yeast two-hybrid analysis
For bait construction with human CA9, cDNA encoding full-length human CA9 was
subcloned into the EcoRI and XhoI restriction enzyme sites of the pLexA cloning
vector. The resulting plasmid, pLexA-CA9, was introduced into yeast strain EGY48
[MATa, his3, trp1, ura3-52, leu2::pLeu2-LexAop6/pSH18-34 (LexAop-lacZ reporter)]
by a modified lithium acetate method (Rho et al., 1996). Human DKK1 was fused
by cloning the cDNA fragments into the EcoRI and XhoI restriction enzyme sites of
pJG4-5 to generate B42 fusion proteins (Clontech, Palo Alto, CA). The cDNAs
encoding B42 fusion proteins were introduced into the competent yeast cells that
already contained pLexA-CA9 and the transformants were selected for the tryptophan
prototrophy (plasmid marker) on synthetic medium (Ura, His, Trp) containing 2%
(w/v) glucose. The binding activity of the interaction between CA9 and DKK1 was
confirmed by measuring the relative expression level of -galactosidase. -
galactosidase activity was determined according to the previously described method
(Rho et al., 1996).
Co-immunoprecipitation (Co-IP)
To identify the protein interacting partner and targets of CA9, gene-encoding human
CA9 was subcloned into pcDNA3.1 –Flag (Invitrogen) with EcoRI and XhoI
(pcDNA3.1–Flag-CA9). The human DKK1 gene was ligated into pcDNA3.1
(Invitrogen) using EcoRI and XhoI (pcDNA3.1-DKK1). For IP, pcDNA3.1–Flag-
CA9 and pcDNA3.1-DKK1 expression plasmids were cotransfected into HEK 293
cells using Fugene transfection reagent (Roche). Lysates were then incubated with
anti-Flag antibody (Santa Cruz Biotechnology) and precipitated with protein-A-
agarose (GE Healthcare Life Sciences). The precipitated proteins were resolved by
SDS gel electrophoresis, transferred onto Immobilon P membrane (Millipore,
Billerica, MA) and subjected to immunoblot analysis with anti-DKK1 antibody
(Abnova, Walnut, CA) or anti-CA9 antibody using the ECL system (GE Healthcare
Life Sciences).
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